News & Events
News & Events
July 25, 2023
PRO Consortium and eCOA Consortium Announce Publication of an Open Access ArticleC-Path’s PRO Consortium and eCOA Consortium are pleased to announce the publication of an open access article in the Value in Health, titled “Best Practice Recommendations for Electronic Patient-Reported Outcome (ePRO) Dataset Structure and Standardization to Support Drug Development.” This article provides best practice recommendations covering the application of CDISC standards to maintain the integrity of ePRO datasets, reduce stakeholder burden,...
July 18, 2023
C-Path Integrates European Offices to Optimize Global Operations and Collaborative Partnerships
C-Path ts activity in Europe and broaden its global operations. C-Path operates in Europe as a nonprofit organisation that builds consensus among its stakeholders from around the world to improve public health. The organisation shares expertise, data, risks and costs to move regulatory science forward.
March 29, 2023
C-Path Appoints Key Scientific Leaders to Executive RolesTUCSON, Ariz., March 29, 2023 — Critical Path Institute (C-Path) announced today the appointment of three accomplished leaders to key executive roles within the organization. Cheryl D. Coon, Ph.D., joins C-Path as the Vice President for the Clinical Outcome Assessment (COA) Program. Shu Chin Ma, Ph.D., M.Sc., M.Phil., EMBA, has been named Vice President of...
December 16, 2022
eCOA Consortium and PRO Consortium Announce Publication of Two Open Access ArticlesC-Path’s eCOA Consortium and PRO Consortium are pleased to announce the publication of two open access articles in the Journal of Patient-Reported Outcomes, titled “Comparability of a Provisioned Device Versus Bring Your Own Device for Completion of Patient-Reported Outcome Measures by Participants with Chronic Obstructive Pulmonary Disease: Qualitative Interview Findings” and “Comparability of a Provisioned Device Versus Bring Your Own Device for...
September 27, 2022
Global Biopharmaceutical Leader to Usher C-Path in Next Phase of Growth and Innovation
C-Path today named Daniel M. Jorgensen, M.D., MPH, MBA, its Chief Executive Officer (CEO). An experienced leader in drug development, healthcare and business, Jorgensen will continue C-Path’s distinguished reputation of collaboration with global stakeholders, including patient groups, academic institutions, the pharmaceutical industry and regulatory agencies, to set a vision for C-Path’s next phase of growth and innovation. Jorgensen’s tenure as CEO will commence on the first of October.